In vivo studies demonstrated that combinatorial treatment led to a prominent reduction in tumor size and invasive margins, a reduction in the Ki67 proliferation index, and an increase in apoptosis and animal survival rates compared with TMZ monotherapy. The gene discussed is MKI67; the disease is neoplasm.